UNITED STATES ~~SECURITIES AND EXCHANGE COMMISSION~~

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

~~Immage~~CURRENT ~~Biotherapeutics Corp.~~REPORT

~~(Exact~~Pursuant ~~Name~~to Section 13 or 15(d) of ~~Small~~the ~~Business~~Securities ~~Issuer~~Exchange inAct ~~its~~of ~~Charter)~~1934

~~Date~~February ~~of Report (Date of earliest event reported): September 8~~16, ~~2015~~2017

Nevada		8731		68-0682040
(State of Incorporation)		(Primary Standard Classification Code)		(IRS Employer ID No.)

Date of Report (Date of earliest event reported)

~~10411~~IMMAGE ~~Motor~~BIOTHERAPEUTICS ~~City~~CORP. ~~Drive~~(Exact name of registrant as specified in its charter)

Bethesda, MD 20817

Nevada

333-185368

68-0682040

(State or other jurisdiction

of incorporation)

(Commission

File Number)

(IRS Employer

Identification No.)

(Address of Registrant's Principal Executive Offices) (Zip Code)

11041 Motor City Drive, Suite 750

Bethesda, MD

20817

(Address of principal executive offices)

(Zip Code)

(~~480-830-2700~~443) 961-1185

(Registrant'’s telephone number, including area code)

~~____________________________________________________~~IMMAGE BIOTHERAPEUTICS CORP.

(Former ~~Name~~name or ~~Former~~former ~~Address~~address, if ~~Changes~~changed ~~Since~~since ~~Last~~last ~~Report~~report)

~~Securities~~Check the appropriate box below if the Form 8-K is intended to besimultaneously ~~Registered~~satisfy ~~Under~~the ~~Section~~filing ~~12(b)~~obligation of the ~~Act:~~registrant ~~None~~under any of the following provisions:

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ¨ Soliciting material pursuant to beRule ~~Registered~~14a-12 ~~Under~~under ~~Section~~the Exchange Act (17 CFR 240.14a-12) ¨ Pre-commencement communications pursuant to Rule 14d-2(gb) ofunder the Exchange Act: (17 CFR 240.14d-2(b)) ¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

~~Common~~ITEM ~~Stock~~8.01 OTHER EVENTS

$ImMAGE Biotherapeutics Corp.~~001~~, ~~Par~~an ~~Value~~ early-stage biotechnology company focusing on utilization of the immune system to find a better treatment for triple negative breast cancer (TNBC), announced today as completion of the YEi Start in France program.

~~(Title~~The YEi Start in France program is an accelerator designed to help entrepreneurs grow their business in France and Europe. ImMAGE Biotherapeutics was one of ~~Class)~~eight American companies selected to complete an intensive one-week immersion in France in December that provided introductions to an extensive customized business network and connections to the best resources in Europe.

~~Check~~“It ~~the~~was ~~appropriate~~an ~~box~~honor ~~below~~to ifbe included among the ~~Form~~eight ~~8-K~~YEi islaureates ~~intended~~in to2016,” ~~simultaneously~~said ~~satisfy~~ImMAGE ~~the~~Biotherapeutics ~~filing~~President ~~obligation~~and ofCOO ~~the~~Mahesh ~~registrant~~Narayanan. ~~under~~“During ~~any~~the course of the ~~following~~program, ~~provisions~~I ~~(see~~had ~~General~~the ~~Instruction~~opportunity ~~A.2~~to ~~below):~~meet with influential companies and investors, including potential partners and mentors that can support our potential expansion overseas.”

~~☐ Written~~Narayanan ~~communications~~visited ~~pursuant~~a tonumber ~~Rule~~of ~~425~~research ~~under~~and cancer centers that could be potential clinical sites for ImMAGE in the ~~Securities~~future. ~~Act~~Among ~~(17~~the ~~CFR~~centers ~~230~~were Gustave Roussy, a major cancer center in Europe that specializes in breast cancer, especially with early stage clinical trials; EFS, an immunotherapy research center; and CGFL, a research institute that specializes in using imaging to study biodistribution of drugs.~~425)~~

~~☐ Soliciting~~In ~~material~~addition, ~~pursuant~~Narayanan met with companies that have potential to ~~Rule~~collaborate ~~14a-12~~with ~~under~~ImMAGE, including Onxeo, an orphan oncology drug development company with four drugs currently in the ~~Exchange~~pipeline, ~~Act~~and ~~(17~~Oncodesign, ~~CFR~~a ~~240~~preclinical contract research organization.~~14a-12)~~

~~☐ Pre-commencement~~ImMAGE ~~communications~~plans ~~pursuant~~to start collaborating with many of these institutions over the next 12 months. ImMAGE is expecting to ~~Rule~~file ~~14d-2(b)~~for ~~under~~an IND with the ~~Exchange~~FDA ~~Act~~in ~~(17~~2018, ~~CFR~~and ~~240~~hopes to start Phase 1 human trials in both the United States and the EU.~~14d-2(b))~~

~~☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))~~2

~~As used in this report, the terms "we", "us", "our", "our company" "Immage Biotherapeutics "refer to Immage Biotherapeutics Corp., a Nevada corporation.~~SIGNATURES

~~Item~~Pursuant ~~5.03~~to ~~Amendments~~the torequirements ~~Articles~~of the Securities Exchange Act of ~~Incorporation~~1934, orthe ~~Bylaws;~~registrant ~~Change~~has induly ~~Fiscal~~caused ~~Year~~this report to be signed on its behalf by the undersigned hereunto duly authorized.

Effective on September 8, 2015, the Company amended its Bylaws to delete and replace Article VII of the Bylaws of the Corporation as read as follows:

	IMMAGE BIOTHERAPEUTICS CORP.

Date: February 28, 2017	By:	/s/ Zhi Cong Mou
	Name:	Zhi Cong Mou
	Title:	President

~~ARTICLE VII-FISCAL YEAR~~3

The fiscal year of the Corporation shall be fixed, and shall be subject to be change by the Board of Directors from time to time, subject to applicable law. The fiscal year of the Corporation shall be August 31.

The Company will be filing a transitional annual report within the time frames required for the new year-end of August 31, 2105.

Item 9.01 - Financial Statements and Exhibits

Exhibit Number		Description
3.1		Revised Article VII of the Company Bylaws.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	IMMAGE BIOTHERAPEUTICS CORP.
Date: September 10, 2015	By:	/s/ Mou Zhi Cong
		Mou Zhi Cong, Chief Executive Officer

Filing Compare · IMMAGE BIOTHERAPEUTICS CORP.